Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Completes $800M Notes Offering; Buys Back Shares

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Illumina said after the close of the market Friday that it has closed its offering of $800 million principal amount of .25 percent convertible senior notes due 2016.

The San Diego-based firm announced the offering earlier in the week, and said that it also has granted initial purchasers a 30-day option to purchase up to $120 million of additional notes.

Illumina said Friday that it used $314.3 million of the net proceeds from the offering to purchase 4,890,500 shares of its common stock through privately negotiated transactions concurrent with the senior notes offering. In addition, the firm intends to use between $260 million and $390 million to fund conversions of its currently outstanding convertible notes.

Illumina intends to use the balance of the proceeds for general corporate purposes, which could include acquisitions and additional purchases of its common stock.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.